Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ILS-920 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ILS-920 |
| Name | Type | Description |
|---|---|---|
| ILS-920 | DRUG | - |
Inclusion Criteria: * Men or women of nonchildbearing potential * Aged 18 to 50 years inclusive at screening. Exclusion Criteria: * Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease....
ILS-920 is an investigational small molecule being developed for the treatment of acute ischemic stroke. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to evaluate its safety and tolerability.
ILS-920 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
ILS-920 is in Phase 1 clinical development. A Phase 1 study has been completed, which evaluated single ascending doses of the drug in healthy volunteers. The drug is still investigational and has not been approved for any use.
ILS-920 has one completed clinical trial registered as NCT00827190, titled "Study Evaluating Single Ascending Doses Of ILS-920." This Phase 1 study enrolled 16 participants, including healthy volunteers, and was designed to assess the safety and tolerability of the drug.
No, ILS-920 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial was a Phase 1 study in healthy volunteers, and the drug has not yet demonstrated efficacy or received regulatory approval for acute ischemic stroke.